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everal transgenic mouse models have been used to understand the maintenance of tolerance in normal individuals and its breakdown in autoimmunity (1) (2) (3) . From these studies, it has become clear that during B cell development, tolerance to self-Ags occurs through a number of mechanisms including receptor revision, anergy induction, and deletion. These mechanisms purge the naive repertoire of most autoreactive B cells. Nevertheless, some B cells with reactivity to self-Ag are routinely found in the periphery (4, 5) . In systemic lupus erythematosus (SLE), 3 these autoantibodies are directed to a variety of nuclear Ags, including dsDNA (6, 7) .
The loss of tolerance to self-Ags that is characteristic of SLE is a multigenic phenomenon with contributions from both susceptibility and suppressor loci (8 -10) . Genes that control B and T cell function have been implicated in this loss of self-tolerance. The presence of certain MHC class II alleles (11) , T and B cell costimulatory molecules CD40 and CD40 ligand (12, 13) CD28-B7.1 (14, 15) , or BAFF (16) , mutations in apoptosis-regulating genes such as fas, fas ligand, and bcl-2 (17) (18) (19) , and polymorphisms causing differential cytokine release (20 -23) altered FcR function (24 -27) or altered B cell receptor (BCR) signaling (28 -32) have all been shown to modulate disease activity.
We have developed a model of SLE that requires an antigenic trigger. B cell tolerance is lost in nonspontaneously autoimmune BALB/c mice when they are immunized with a multimeric form of a peptide mimetope of dsDNA (DWEYSVWLSN-MAP, MAP peptide). These mice develop high titers of anti-peptide Abs, antidsDNA Abs, and Abs to a variety of nuclear Ags, as well as glomerular Ig deposition (33, 34) . This loss of self-tolerance is T cell dependent and requires activation of E d -restricted helper T cells (35) . The T cells that respond to MAP peptide recognize an epitope derived from both the decapeptide and the polylysine backbone, and display no evidence of cross-reactivity with self-Ag.
Disease induction is genetically determined. DBA/2 mice, like BALB/c mice, express the H-2 d haplotype, but do not develop anti-DNA Abs following peptide immunization. We have determined that the resistance of DBA/2 mice to autoreactivity in this model resides in the B cell compartment. DBA/2 B cells display an increased strength of BCR signaling that leads to greater apoptosis of naive B cells and more stringent negative selection of naive B cells. The resulting peripheral B cell repertoire is less capable of mounting an autoantibody response and thus mediates resistance to an Ag-triggered lupus-like phenotype.
Materials and Methods

Mice
Eight-to 10-wk-old female wild-type BALB/c, DBA/2, (BALB/c ϫ DBA/ 2)F 1 mice and SCID BALB/c mice were purchased from either Taconic Farms (Germantown, NY) or The Jackson Laboratory (Bar Harbor, ME). Mice were housed in the Albert Einstein College of Medicine animal (specific pathogen free) barrier facility or in the barrier facility of The Rockefeller University.
Antigens
The peptide DWEYSVWLSN linked to an eight-branch polylysine backbone (DWEYSVWLSN-MAP) was purchased from Research Genetics (Huntsville, AL) and its purity and/or sequence verified by either HPLC or amino acid analysis.
T cell proliferation assay
BALB/c mice were immunized in the right footpads with 100 g of MAP peptide in 100 l of PBS/CFA H37 Ra (1/1) and in the left footpads with 100 l of PBS/CFA H37 Ra (1/1) alone. One week later, cells from the left or right popliteal, axillary, and brachial lymph nodes were harvested separately in RPMI 1640 medium (Life Technologies, Grand Island, NY) supplemented with 5% FCS, 2 mM glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 50 M 2-ME. Cells were pulsed with various doses of MAP peptide or purified protein derivative (PPD) in triplicate for 72 h.
In order not to activate T cells during the isolation procedure, T cells were purified by negative selection using anti-A b,d,a and anti-E d, k , anti-F4/80 (TIB120, HB-198; American Type Culture Collection (ATCC), Manassas, VA), and anti-B220 (BD PharMingen, San Diego, CA) Abs. After depletion, more than 95% of the remaining cells were CD3-positive cells. B cells were purified by incubation with 2.5 g/ml biotinylated anti-CD43 Ab (clone S7) to eliminate B1 and plasma cells (36) To determine the MHC restriction for MAP peptide, lymph node T cell proliferation assays were conducted as described above in the presence of 50 g/ml MAP peptide and blocking Abs to I-A d (MKD6, ATCC HB-3) and I-E d (1444S, ATCC HB-32; ATCC). These Abs were purified from ascites produced by inoculation of SCID mice with the above cell lines. The purity of the Igs was verified by SDS-PAGE and their concentration was measured by both absorbance at 280 nm and by quantitative ELISA (37) .
Cytokine ELISAs
Lymph node T cell proliferation assays were performed as described above. After 72 h, supernatants from each well were tested for the presence of IL-2, IL-4, IFN-␥, IL-10, and IL-12 using the Endogen mouse cytokine ELISA kits (Woburn, MA). TGF-␤1 was assayed using the human cytokine ELISA kit from R&D Systems (Minneapolis, MN). Cytokine concentrations were determined based on standard curves.
ELISPOT assays
Immulon II 96-well plates (Dynatech Laboratories, Chantilly, VA) were coated with 50 l of either 10 or 100 g/ml calf thymus dsDNA overnight at 37°C. Purified B cells were cultured for 48 h with or without LPS (10 g/ml; Sigma-Aldrich, St. Louis, MO) in RPMI 1640 medium containing 10% FCS at 37°C. B cells were then added to peptide or dsDNA-coated Immulon II plates for 8 h. Biotin-conjugated goat anti-mouse Ab (Southern Biotechnology Associates, Birmingham, AL) diluted 1:1000 was added, followed by 50 l of streptavidin conjugated to alkaline phosphatase (Southern Biotechnology Associates) and 50 l of 5-bromo-4-chloro-3-indolyl phosphate/1 mg/ml disodium salt (Sigma-Aldrich) in AMP buffer (1 M MgCl 2 , 0.01% Triton X-405, 9.58% amino-2-methyl-1-propanol (pH 9.8); Sigma-Aldrich). Plates were allowed to develop at room temperature. Spots were counted using an Olympus sZX9 dissecting microscope (Olympus, De Plapo, Japan).
Apoptosis assay
Naive B cells were purified and cultured with different concentrations of biotin-conjugated anti-IgM Ab (Southern Biotechnology Associates) for 1 h at 37°C in RPMI 1640 medium with 5% FCS followed by neutralite avidin (Southern Biotechnology Associates) at a 2:1 ratio to anti-IgM Ab. Cells were stained with anti-B220 Ab, fixed in 1% paraformaldehyde, and incubated with 0.4 g/ml rabbit polyclonal Ab to activated caspase 3 (clone CM1; Idun Pharmaceuticals, La Jolla, CA) or irrelevant rabbit polyclonal Ig followed by PE-labeled goat anti-rabbit Ab (BD PharMingen). Flow cytometry was performed with a FACSCalibur flow cytometer (BD Biosciences, Mountain View, CA) and analysis was performed using FlowJo software (Tree Star, San Carlos, CA).
Calcium mobilization
For measurements of calcium responses after anti-IgM stimulation, 10 7 splenocytes were loaded with 5 g/ml Indo-1 AM (1-[2-amino-5-(6-carboxy-2-indolyl)phenoxy]-2-(2-amino-5-methylphenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid, pentaacetoxymethyl ester; Molecular Probes, Eugene, OR) at 37°C for 30 -60 min and then stained with anti-B220 (RA3-6b2; BD PharMingen) and stimulated with goat F(abЈ) 2 anti-IgM Ab (Southern Biotechnology Associates). The ratio of fluorescence in violet (400 nm) vs blue (510 nm) was measured with a FACSorter (BD Biosciences).
Statistics
Comparisons between two groups were performed using the unpaired Student's t test. Error bars represent SEM values. Values of p Ͻ 0.05 were considered to be statistically significant.
Results
DBA/2 mice do not mount a serum response to MAP peptide immunization
BALB/c and DBA/2 mice were immunized with MAP peptide. By week 6, the IgG response to both peptide and DNA was significantly greater in BALB/c mice than in DBA/2 mice (Fig. 1) . There was no significant response to dsDNA in DBA/2 mice following immunization and no glomerular Ig deposition. Thus, there is no pathogenic anti-DNA response present in peptide-immunized DBA/2 mice.
DBA/2 mice mount a T cell response to MAP peptide
To determine whether there was a difference in T cell function between DBA/2 and BALB/c mice that might explain the lack of serum response in DBA/2 mice, we analyzed the T cell response to peptide in DBA/2 mice. DBA/2 T cells mounted a T proliferative response to the peptide ( Fig. 2A) . In fact, while proliferation to PPD was similar for DBA/2 and BALB/c T cells, T cell proliferation to the peptide was higher in the DBA/2 mice. In BALB/c mice, the antipeptide response is mediated by CD4 E d -restricted T cells (35) . The T cell response in DBA/2 mice is E d restricted as well, since Ab to E d was able to block T cell proliferation to the peptide from maximal to background levels in a dose-dependent manner, whereas the isotype-matched control Ab to A d had no effect (data not shown). Furthermore, cytokine production by Agspecific T cells was the same in BALB/c and DBA/2 mice (Fig.  2B ). Primed T cells from both strains produced IL-2 and IFN-␥ in response to MAP peptide exposure, but produced no IL-4 or TGF-␤.
B cells from DBA/2 mice are responsible for the lack of serum response to MAP peptide
To test whether B cells from DBA/2 mice were responsible for the lack of anti-DNA Ab after peptide immunization, an adoptive transfer experiment was performed. T cells from (BALB/c ϫ DBA/2)F 1 mice and B cells from either BALB/c or DBA/2 mice were transferred into BALB/c SCID mice. After 14 days, reconstituted mice were immunized with MAP peptide. SCID mice that received naive B cells from DBA/2 mice displayed fewer B cells secreting Ab to peptide and to dsDNA than SCID mice that received naive B cells from BALB/c mice (Fig. 3) . There was no difference in the number of surviving B cells. Since the non-B cell APC and the T cells are the same in the recipient mice in this study, the difference in B cell activation must reflect an intrinsic feature of the B cell population.
We reasoned that the activation of DBA/2 B cells might reflect an impaired interaction between Ag-specific T and B cells. Agresponsive T cells would be unable to activate DBA/2 B cells if the B cells failed to process and present the same peptide epitope that was presented by dendritic cells to prime the T cell response. To address this possibility, we assayed DBA/2 and BALB/c B cells isolated from naive mice for their ability to present MAP peptide to primed T cells. Naive DBA/2 B cells can present MAP peptide to primed T cells as efficiently as naive BALB/c B cells (Fig. 4) . This observation confirmed that the lack of Ab response represented a strain-specific difference in B cell repertoire or activation and not a difference in Ag presentation.
The remaining explanation for the reduced response in DBA/2 mice was an alteration in the repertoire of B cell antigenic specificities. To test for this possibility, we assayed for anti-peptide and anti-dsDNA Ab-secreting B cells in the naive B cell repertoire. DBA/2 mice showed a significantly lower frequency of B cells with each specificity (Fig. 5A ). Resting and anergized B cells will not spontaneously secrete Ab, but can be activated with LPS (38) . To assay for their presence in DBA/2 mice, we stimulated splenic B cells with LPS. As shown in Fig. 5B , DBA/2 mice have significantly fewer peptide-reactive and dsDNA-reactive B cells than BALB/c mice following LPS stimulation. There was no difference in LPS responsiveness between strains because there was no difference in the number of B cells that were activated to produce Ab in DBA/2 and BALB/c mice (data not shown). Since cross-linking BCRs induced a higher rate of apoptosis in DBA/2 B cells, we analyzed the strength of signaling through the BCR. When we stimulated B220 ϩ cells with anti-IgM, the calcium response was greater in DBA/2 B cells (Fig. 6B) . The increased strength of BCR signaling is consistent with the greater apoptosis induced by anti-IgM Ab and with a lower threshold for BCR signaling in DBA/2 mice. Thus, it follows that autoreactive B cells would be deleted on exposure to lower concentrations of Ag in DBA/2 mice, negative selection would be more stringent, and B cells having BCRs with lower affinity for self-Ag would be deleted.
Discussion
The maintenance of self-tolerance is a major challenge to the immune system. Many dysfunctions in immune cell regulation lead to a lupus-like phenotype. The models of SLE that have been most extensively studied are the MRL/1pr and the NZB/W F 1 mouse strains. These strains both develop a SLE-like disease spontaneously and display not only autoantibody production but also an abnormality of the T cell repertoire or of T cell function (40, 41) . We have developed a mouse model of SLE-like autoimmunity that requires both a genetic predisposition and exposure to an environmental factor for disease expression. The model we use has the advantage of being precipitated by a known antigenic stimulus, a peptide mimetope for dsDNA. Thus, Ag-specific T cells and B cells can be characterized. This SLE-like syndrome, characterized by the production of anti-peptide and anti-dsDNA Abs as well as glomerulonephritis, is dependent on E d -restricted CD4 ϩ Th1 cells (35) . Previous studies have shown there is no evidence that the peptide-reactive T cells are autoreactive. Thus, this model is one in which T cells that are activated by foreign Ag provide help for cross-reactive anti-peptide and anti-DNA B cells, and autoreactivity lies within the B cell compartment.
In this study, we show that DBA/2 mice, which share the MHC haplotype with BALB/c mice, mount a less robust humoral response to MAP peptide and thus avoid pathologic autoreactivity. The titer of anti-peptide and anti-DNA Abs is ϳ8-fold greater in BALB/c mice (data not shown). In clinical assays, a titer of antinuclear Ab of 1:40 is considered normal, whereas a titer of 1:160 is consistent with SLE. Thus, in the clinic, even 4-fold increases in Ab titer can make a significant difference with respect to disease expression.
Data from studies of the T cell response to MAP peptide and adoptive transfer studies with DBA/2 or BALB/c B cells and F 1 T cells demonstrated that an intrinsic B cell difference accounts for the diminished Ab response to peptide in DBA/2 mice. This is the only model of induced autoimmune disease in which genetic susceptibility to disease has been shown to be exclusively a B cell property. The absence of a cross-reactive anti-DNA response results from a "hole" in the repertoire of B cell antigenic specificities. An explanation for this hole or absence of potentially autoreactive B cells comes from the studies of BCR signaling and BCR-induced apoptosis in BALB/c and DBA/2 mice. There is greater BCR signaling and greater susceptibility to negative selection in DBA/2 B cells. We and others have previously shown that splenic B cells that undergo apoptosis following BCR signaling are transitional B cells (42) (43) (44) . During B cell development, B cells with autospecificity are deleted or anergized, markedly reducing the potential for autoantibody production. Studies of mice with transgene-encoded BCRs have demonstrated that there is a threshold of BCR ligation required for signaling for tolerance induction (45) . Studies of transgenic mice overexpressing molecules involved in BCR signaling have shown that this threshold is genetically determined (28 -32) and that B cells that may ordinarily be tolerized are indifferent, or fail to be signaled by autoantigen, if the strength of BCR signaling is altered.
Craft and colleagues (46) have demonstrated an altered threshold for T cell activation in MRL mice with T cells from this autoimmune background showing greater TCR signaling in response to a low affinity ligand than T cells from a nonautoimmune background. T cell hyperresponsiveness appears to map to a SLE susceptibility locus in NZM mice (47) . In our model, there is no evidence for altered T cell function. DBA/2 T cells recognize MAP peptide. Furthermore, both BALB/c and DBA/2 T cells up-regulated IL-2 and IFN-␥ in a dose-dependent fashion, whereas IL-4 and TGF ␤ levels were unchanged. Overall, these results indicate that the T cell response does not account for the maintenance of self-tolerance in DBA/2 mice.
Studies of transgenic mice and mice with targeted gene deletions have demonstrated that alterations in expression of BCR coreceptors, components of the BCR or coreceptor signaling cascades, FcRII, or costimulatory molecules can affect thresholds for B cell survival and activation. In these animals, differences in levels of protein expression are dramatic and the mice display spontaneous autoimmune disease. Our data demonstrate that a B cell autonomous difference between two nonspontaneously autoimmune hosts can predispose to Ag-induced autoimmunity. Each strain, in the absence of immunization with MAP peptide, is immunocompetent with no detectable compromise in immune function. DBA/2 B cells, however, display enhanced BCR signaling to Ag. This results in enhanced apoptosis of immature cells in response to the same antigenic stimulus. It is consistent with previous reports that splenic DBA/2 B cells have a more activated phenotype than splenic BALB/c B cells and are more responsive to proliferative signals (48) . Interestingly, it is also consistent with studies of the Ab response to N-acetyl glucosamine coupled to BSA in BALB/c and DBA/2 mice. The BALB/c response displays significantly more cross-reactivity with cardiac myosin (A. Kuan and B. Diamond, unpublished data). Thus, the DBA/2 cell repertoire cannot be easily induced to autoreactivity.
Although some models of lupus are characterized by B cell hyperactivity, this study suggests that a diminished response to Ag can result in autoimmunity due to diminished tolerance induction. Interestingly, it has recently been shown that the sle1 susceptibility locus of the NZM mouse leads to up-regulation of CD22, an inhibitory coreceptor to the BCR (49) .
This study shows that the threshold needed for negative selection or central tolerance of B cells determine whether a host is susceptible or resistant to Ag-induced autoimmunity. Strain-specific differences in this threshold may be subtle and, under most circumstances, may not adversely affect immune function. Certain antigenic stimuli, however, may reveal a genetic predisposition to greater autoreactivity. It is certainly the case that autoantibodies arise in the course of a response to many microbial pathogens. In some individuals, this autoreactivity may achieve a sufficient titer to cause tissue damage.
A critical difference between BALB/c and DBA/2 appears to reside in the strength of BCR signaling. Molecules that regulate strength of BCR signaling may, therefore, constitute an important new therapeutic target in SLE. We would speculate that there exists a subset of individuals with a B cell autonomous predisposition to autoreactivity and to SLE. Interventions that alter the strength of BCR signaling without altering the B cell-T cell interface or the T cell repertoire may have a therapeutic potential.
